Co-Authors
This is a "connection" page, showing publications co-authored by Matthew Frieman and James Logue.
Connection Strength
0.857
-
The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30687-30698.
Score: 0.228
-
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. J Virol. 2020 10 14; 94(21).
Score: 0.227
-
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat Biomed Eng. 2021 08; 5(8):815-829.
Score: 0.059
-
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021 04 13; 325(14):1467-1469.
Score: 0.059
-
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms. ACS Omega. 2021 Mar 23; 6(11):7454-7468.
Score: 0.058
-
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 01 14; 12(1):372.
Score: 0.058
-
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020 12 04; 370(6521).
Score: 0.057
-
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 12 10; 383(24):2320-2332.
Score: 0.056
-
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020 08 21; 369(6506):1010-1014.
Score: 0.055